The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Treatment of multiple sclerosis with gamma interferon: Exacerbations associated with activation of the immune system
Open accessAbstract
We treated 18 clinically definite relapsing-remitting MS patients with recombinant gamma interferon in a pilot study designed to evaluate toxicity and dosage. Patients received low (1 microgram), intermediate (30 micrograms), or high (1,000 micrograms) doses of interferon by intravenous infusion twice a week for 4 weeks. Serum levels of gamma interferon were proportional to dose and no interferon was detected in CSF. Seven of the 18 patients had exacerbations during treatment, a significant increase compared with the prestudy exacerbation rate (p less than 0.01). Exacerbations occurred in all three dosage groups and were not precipitated by fever or other dose-dependent side effects. There were significant increases in circulating monocytes bearing class II (HLA-DR) surface antigen, in the proliferative responses of peripheral blood leukocytes, and in natural killer cell activity. These results show that systemic administration of gamma interferon has pronounced effects on cellular immunity in MS and on disease activity within the CNS, suggesting that the attacks induced during treatment were immunologically mediated. Gamma interferon is unsuitable for use as a therapeutic agent in MS. Agents that specifically inhibit gamma interferon production or counteract its effects on immune cells should be investigated as candidates for experimental therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
Exacerbations of multiple sclerosis in patients treated with gamma interferon
Panitch, H., Haley, A., Hirsch, R., & Johnson, K. (1987) · The Lancet · doi:10.1016/s0140-6736(87)92863-7 · Cited by 1,071
Self-citationCLINICAL VIRAL INFECTIONS AND MULTIPLE SCLEROSIS
SIBLEY, W. (1985) · The Lancet · doi:10.1016/s0140-6736(85)92801-6 · Cited by 594
Recombinant interferon-gamma increases HLA-DR synthesis and expression.
Basham, T. Y., & Merigan, T. C. (1983) · The Journal of Immunology · doi:10.4049/jimmunol.130.4.1492 · Cited by 575
Fierz, W., Endler, B., Reske, K., Wekerle, H., & Fontana, A. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.134.6.3785 · Cited by 443
Traugott, U., Reinherz, E. L., & Raine, C. S. (1983) · Journal of Neuroimmunology · doi:10.1016/0165-5728(83)90036-x · Cited by 315
Hafler, D. A., Fox, D. A., Manning, M. E., Schlossman, S. F., Reinherz, E. L., & Weiner, H. L. (1985) · New England Journal of Medicine · doi:10.1056/nejm198505303122201 · Cited by 304
A neurologic rating scale (NRS) for use in multiple sclerosis
Sipe, J. C., Knobler, R. L., Braheny, S. L., Rice, G. P. A., Panitch, H. S., & Oldstone, M. B. A. (1984) · Neurology · doi:10.1212/wnl.34.10.1368 · Cited by 255
Self-citationLing, P. D., Warren, M. K., & Vogel, S. N. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.135.3.1857 · Cited by 209
Intrathecal Interferon Reduces Exacerbations of Multiple Sclerosis
Jacobs, L., O'Malley, J., Freeman, A., & Ekes, R. (1981) · Science · doi:10.1126/science.6171035 · Cited by 209
Sobel, R. A., Blanchette, B. W., Bhan, A. K., & Colvin, R. B. (1984) · The Journal of Immunology · doi:10.4049/jimmunol.132.5.2402 · Cited by 197
Kelley, V. E., Fiers, W., & Strom, T. B. (1984) · The Journal of Immunology · doi:10.4049/jimmunol.132.1.240 · Cited by 180
Multiple Sclerosis as a Disease of Immune Regulation
Waksman, B. H., & Reynolds, W. E. (1984) · Experimental Biology and Medicine · doi:10.3181/00379727-175-41798 · Cited by 167
Sriram, S., & Steinman, L. (1983) · The Journal of experimental medicine · doi:10.1084/jem.158.4.1362 · Cited by 160
Systemic alpha‐interferon therapy of multiple sclerosis
Knobler, R. L., PANITCH, H. S., Braheny, S. L., Sipe, J. C., Rice, G. P., Huddlestone, J., Francis, G. S., Hooper, C. J., Kamin‐Lewis, R., Johnson, K. P., et al. (1984) · Neurology · doi:10.1212/wnl.34.10.1273 · Cited by 128
Self-citationMcCarron, R. M., Spatz, M., Kempski, O. S., Hogan, R. N., Muehl, L. A., & McFarlin, D. E. (1986) · The Journal of Immunology · doi:10.4049/jimmunol.137.11.3428 · Cited by 118
Jacobs, L. R., Herndon, R. M., Freeman, A. I., Cuetter, A. C., Smith, W., Salazar, A., Reese, P. A., Josefowicz, R., Husain, F., Ekes, R., et al. (1986) · The Lancet · doi:10.1016/s0140-6736(86)92730-3 · Cited by 112
Distribution of alpha interferon in serum and cerebrospinal fluid after systemic administration
Smith, R. A., Norris, F. H., Palmer, D., Bernhardt, L., & Wills, R. J. (1985) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1985.16 · Cited by 103
Interferon responses of leukocytes in multiple sclerosis
Neighbour, P. A., Miller, A., & Bloom, B. R. (1981) · Neurology · doi:10.1212/wnl.31.5.561 · Cited by 96
Lymphocytes from multiple sclerosis patients produce elevated levels of gamma interferonin vitro
Hirsch, R. L., PANITCH, H. S., & Johnson, K. P. (1985) · Journal of Clinical Immunology · doi:10.1007/bf00915335 · Cited by 93
Self-citationSystemic Recombinant -2Interferon Therapy in Relapsing Multiple Sclerosis
Camenga, D. L., Johnson, K. P., Alter, M., Engelhardt, C., Fishman, P. S., Greenstein, J. I., Haley, A., Hirsch, R. L., Kleiner, J. E., Kofie, V., et al. (1986) · Archives of Neurology · doi:10.1001/archneur.1986.00520120023011 · Cited by 75
Self-citationA serial study of peripheral blood T lymphocyte subsets in relapsing–remitting multiple sclerosis
Kastrukoff, L. F., & Paty, D. W. (1984) · Annals of Neurology · doi:10.1002/ana.410150308 · Cited by 53
Evidence for antigen presentation in situ by endothelial cells and astrocytes
Traugott, U., & Raine, C. S. (1985) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(85)90147-9 · Cited by 51
Vervliet, G., Claeys, H., Haver, H. V., Carton, H., Vermylen, C., Meulepas, E., & Billiau, A. (1983) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(83)90133-8 · Cited by 47
Cited by
Immunology of multiple sclerosis
Sospedra, M., & Martin, R. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115707 · Cited by 2,149
Steinman, L. (2007) · Nature Medicine · doi:10.1038/nm1551 · Cited by 1,376
T cell subsets and their signature cytokines in autoimmune and inflammatory diseases
Raphael, I., Nalawade, S., Eagar, T. N., & Forsthuber, T. G. (2015) · Cytokine · doi:10.1016/j.cyto.2014.09.011 · Cited by 1,160
Interferons at age 50: past, current and future impact on biomedicine
Borden, E. C., Sen, G. C., Uze, G., Silverman, R. H., Ransohoff, R. M., Foster, G. R., & Stark, G. R. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2422 · Cited by 1,154
Multiple Sclerosis: Mechanisms and Immunotherapy
Baecher-Allan, C., Kaskow, B. J., & Weiner, H. L. (2018) · Neuron · doi:10.1016/j.neuron.2018.01.021 · Cited by 938
Metadata
- Authors
- Panitch, H. S., Hirsch, R. L., Schindler, J., & Johnson, K. P.
- Venue
- Neurology
- Published
- 1987-07
- Volume
- 37
- Issue
- 7
- Pages
- 1097-1097
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2142177598
- Cited by
- 751
- References
- 24
- FWCI
- 15.38
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.